Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts

By Avik Chatterjee; Michelle Weitz; Alexandra Savinkina, et al

Key Points - Question: Is provision of medications for opioid use disorder (MOUD) during incarceration associated with fewer overdose deaths? Findings: This economic evaluation of a model of the natural history of OUD in Massachusetts found that a strategy offering buprenorphine, methadone, and naltrexone during incarceration was associated with 192 fewer overdose deaths (a 1.8% reduction) and was less costly than a naltrexone-only strategy averting 95 overdose deaths (a 0.9% reduction). The 3-MOUD strategy was also cost-effective at $7252 per quality-adjusted life-year gained. Meaning These findings suggest that offering 3 MOUDs during incarceration is a life-saving, cost-effective intervention

JAMA Network Open. 2023;6(4):e237036. doi:10.1001/jamanetworkopen.2023.7036